| Götze, Katharina |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
| Recruiting | 3 | 70 | Europe | Luspatercept, Reblozyl | GWT-TUD GmbH, Celgene | Myelodysplastic Syndromes | 12/24 | 06/25 | | |
| Recruiting | 2 | 28 | Europe | Pembrolizumab, PEM, Keytruda®, Azacitidine, AZA, Vidaza® | Technische Universität Dresden, Merck Sharp & Dohme LLC | Acute Myeloid Leukemia | 12/25 | 12/26 | | |
IMpress, NCT05583552: Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy |
|
|
| Active, not recruiting | 2 | 46 | Europe, RoW | Imetelstat sodium, GRN163L | GCP-Service International West GmbH, Geron Corporation, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, QIMR Berghofer Medical Research Institute, Australasian Leukaemia and Lymphoma Group, Groupe Francophone des Myelodysplasies, German Myelodysplastic Syndrome Study Group | Myelodysplastic Syndromes, Acute Myeloid Leukemia | 02/25 | 06/26 | | |
LUCAS, NCT05178342: Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 |
|
|
| Terminated | 2 | 38 | Europe | CA-4948, Emavusertib | University of Leipzig, Curis, Inc. | Myelodysplastic Syndromes, Anemia | 07/24 | 07/24 | | |
VENAZA-5S, NCT05833438: Venetoclax in Combination with 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy |
|
|
| Recruiting | 2 | 45 | Europe | VEN+AZA-5 | University of Leipzig, AbbVie, University Hospital Leipzig, Hematology Diagnostics Laboratory, University of Leipzig, Clinical Trial Centre (ZKS) | Acute Myeloid Leukemia (AML) | 04/25 | 07/25 | | |
LENNON, NCT05384691: Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions |
|
|
| Recruiting | 2 | 213 | Europe | Luspatercept Injection, LUS | University of Leipzig, Celgene Corporation | Myelodysplastic Syndromes, Anemia | 07/26 | 07/27 | | |
NCT05237713: Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients |
|
|
| Terminated | 2 | 10 | Europe | Canakinumab Injection, Ilaris(R) | University of Leipzig, Novartis Pharmaceuticals | Anemia, Myelodysplastic Syndromes | 02/24 | 02/24 | | |
